EC ap­proves Ab­b­Vie's upadac­i­tinib as first JAK in­hibitor for atopic der­mati­tis

Un­like the FDA, the Eu­ro­pean Com­mis­sion isn’t hes­i­tat­ing be­fore hand­ing mar­ket­ing au­tho­riza­tion to Rin­voq as the first JAK in­hibitor to treat mod­er­ate and se­vere atopic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER